EGFR Ligands Differentially Stabilize Receptor Dimers to Specify Signaling Kinetics
Abstract not provided
SEARCH · Engineering Papers
Search indexed NASA NTRS and DOE OSTI research on propulsion, heat transfer, battery materials and energy systems. Follow report and document links to the original sources.
Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.
Abstract not provided
Abstract not provided
Purpose: To describe the radiographic and histopathologic changes after stereotactic radiosurgery (SRS) and epidermal growth factor receptor inhibition in patients with recurrent malignant gliomas. Methods and Materials: A total of 15 patients with recurrent high-grade gliomas were treated on a prospective Phase I trial combining SRS and gefitinib. The SRS dose was escalated from 18 to 36 Gy in three fractions. The planning target volume was the T{sub 1}-weighted contrast-enhancing (T{sub 1}C) lesion plus 2 mm. Gefitinib was given at 250 mg daily. Serial brain magnetic resonance imaging scans were analyzed to characterize the volumetric changes in the T{sub 1}C and T{sub 2} abnormalities after treatment. Two patients underwent resection for suspected recurrence. Results: The median pretreatment magnetic resonance imaging T{sub 1}C and T{sub 2} volume was 40.9 and 184.1 cm{sup 3}, respectively. The median post-SRS percentage of increases in the T{sub 1}C volume at 1, 2-4, and 5-7 months was 8.9%, 41.3%, and 99.6%, respectively. The median percentage increase in the T{sub 2} volume likewise showed a trend upward after SRS, from 18.0% at 1 month to 37.8% at 5-7 months. For the 2 patients who underwent resection after SRS for an increasing T{sub 1}C volume, the histopathologic analysis revealed therapy-induced vascular injury and necrosis. One patient with an asymptomatic increase in the T{sub 1}C volume after SRS was treated conservatively. After a peak T{sub 1}C volume increase at 9 months, the T{sub 1}C volume had declined to 50% of the maximal volume at 15 months. The patients with the most dramatic increase in T{sub 1}C volume experienced the longest overall survival. Conclusion: Patients experienced a notable increase in magnetic resonance imaging T{sub 1}C and T{sub 2} volumes after the combination of SRS and epidermal growth factor receptor inhibition. The tissue changes were consistent with a potent treatment effect.
Purpose: Systemic therapies when added to whole brain radiotherapy have failed to improve the survival of patients with multiple brain metastases. The epidermal growth factor receptor antibody cetuximab is an attractive option, if it is able to cross the blood-brain barrier. This might be proven with molecular imaging if the radiolabeled antibody is stable long enough to be effective. This study investigated the stability of radiolabeled cetuximab (Erbitux) ({sup 131}I-Erbi) and potential synergistic effects with radiotherapy in vitro. Methods and Materials: Two cell lines were investigated, A431 with numerous epidermal growth factor receptors, and JIMT without epidermal growth factor receptors. We labeled 0.4 mg cetuximab with 50 MBq of [{sup 131}I] iodide. Stability was determined for 72 h. The cell cultures were incubated with {sup 131}I-Erbi or cold cetuximab for 72 h. Uptake and cell proliferation were measured every 24 h after no radiotherapy or irradiation with 2, 4, or 10 Gy. Results: The radiolabeling yield of {sup 131}I-Erbi was always >80%. The radiochemical purity was still 93.6% after 72 h. A431 cells showed a {sup 131}I-Erbi uptake about 100-fold greater than the JIMT controls. After 48 h, the A431 cultures showed significantly decreased proliferation. At 72 h after irradiation, {sup 131}I-Erbi resulted in more pronounced inhibition of cell proliferation than the cold antibody in all radiation dose groups. Conclusion: {sup 131}I-Erbi was stable for <=72 h. Radiotherapy led to increased tumor cell uptake of {sup 131}I-Erbi. Radiotherapy and {sup 131}I-Erbi synergistically inhibited tumor cell proliferation. These results provide the prerequisite data for a planned in vivo study of whole brain radiotherapy plus cetuximab for brain metastases.
Abstract not provided
Abstract not provided
Explore the source record for details and available documents.
Abstract not provided
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Abstract not provided
Abstract not provided
Abstract not provided